MicroRNA-Responsive DNA-Programmed Nanomedicine with Controllability of Cascaded Events for Cancer Therapy Enhancement

ACS Macro Lett. 2021 Jun 15;10(6):654-661. doi: 10.1021/acsmacrolett.1c00136. Epub 2021 May 10.

Abstract

Chemotherapy is a prime tool for cancer clinical therapy. The effectiveness has been improved considerably with the assistance of nanotechnology. However, it still meets the challenge of unsatisfied therapeutic effects caused by multidrug resistance and uncontrollable drug release. For further enhancement of the treatment performance, we develop a kind of microRNA-responsive nanomedicine that uses the biomarker microRNA-21 as a trigger of cascaded killing effects on cancer cells, including chemotherapy and gene silencing. The nanomedicine consists of a gold nanoparticle core and a DNA layer. Strand migrations within the layer can accurately control the events of anticancer drug doxorubicin release and multidrug-resistant-associated protein 1 downregulation, yielding an alleviation of multidrug resistance and enhanced killing on cancer cells. This work demonstrates a microRNA-responsive nanomedicine in combination with chemotherapy and gene silencing, which paves the way to the advancement of DNA-based nanomedicine for cancer theranostics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA
  • Gold
  • Metal Nanoparticles* / therapeutic use
  • MicroRNAs* / genetics
  • Nanomedicine
  • Neoplasms* / drug therapy

Substances

  • MicroRNAs
  • Gold
  • DNA